ATE429442T1 - Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie - Google Patents

Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie

Info

Publication number
ATE429442T1
ATE429442T1 AT02797061T AT02797061T ATE429442T1 AT E429442 T1 ATE429442 T1 AT E429442T1 AT 02797061 T AT02797061 T AT 02797061T AT 02797061 T AT02797061 T AT 02797061T AT E429442 T1 ATE429442 T1 AT E429442T1
Authority
AT
Austria
Prior art keywords
compositions
polypeptide
methods
specific immunotherapy
presenting
Prior art date
Application number
AT02797061T
Other languages
English (en)
Inventor
Alexander Gaiger
Patricia Mcneill
Nomalie Jaya
Darrick Carter
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/002,603 external-priority patent/US7901693B2/en
Priority claimed from US10/125,635 external-priority patent/US20030039635A1/en
Priority claimed from US10/195,835 external-priority patent/US7655249B2/en
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE429442T1 publication Critical patent/ATE429442T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AT02797061T 2001-10-30 2002-10-30 Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie ATE429442T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/002,603 US7901693B2 (en) 1998-09-30 2001-10-30 Compositions and methods for WT1 specific immunotherapy
US10/125,635 US20030039635A1 (en) 1998-09-30 2002-04-16 Compositions and methods for WT1 specific immunotherapy
US10/195,835 US7655249B2 (en) 1998-09-30 2002-07-12 Compositions and methods for WT1 specific immunotherapy
US10/244,830 US20030235557A1 (en) 1998-09-30 2002-09-16 Compositions and methods for WT1 specific immunotherapy
PCT/US2002/035194 WO2003037060A2 (en) 2001-10-30 2002-10-30 Compositions and methods for wt1 specific immunotherapy

Publications (1)

Publication Number Publication Date
ATE429442T1 true ATE429442T1 (de) 2009-05-15

Family

ID=27485189

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02797061T ATE429442T1 (de) 2001-10-30 2002-10-30 Zusammensetzungen und verfahren zur wt1- spezifischen immuntherapie

Country Status (14)

Country Link
US (1) US20030235557A1 (de)
EP (2) EP2172476A3 (de)
JP (1) JP4391232B2 (de)
KR (1) KR100970854B1 (de)
CN (1) CN100471868C (de)
AT (1) ATE429442T1 (de)
AU (1) AU2002361584B2 (de)
CA (1) CA2465303C (de)
CY (1) CY1111002T1 (de)
DE (1) DE60232102D1 (de)
DK (1) DK1468014T3 (de)
ES (1) ES2326311T3 (de)
NZ (2) NZ560858A (de)
WO (1) WO2003037060A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1038929B (zh) * 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
EP1371664B1 (de) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti-modifiziertes peptid
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
CA2530184C (en) * 2003-06-27 2015-10-06 Haruo Sugiyama Method of selecting patients suitable for wt1 vaccine
AU2004273034A1 (en) * 2003-09-05 2005-03-24 Sanofi Pasteur Limited Multi-antigen vectors for melanoma
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
EP2478913A1 (de) * 2003-12-01 2012-07-25 Sloan-Kettering Institute For Cancer Research Synthetische HLA-bindende Peptidanaloga und Verwendungen dafür
WO2005087260A1 (en) * 2004-03-04 2005-09-22 Corixa Corporation Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
JP4886507B2 (ja) * 2004-03-31 2012-02-29 株式会社癌免疫研究所 Ｗｔ１由来の癌抗原ペプチド
EP1657250A1 (de) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin HLA-A*01 bindendes T-Zell-Epitop von WT1
CA2626238C (en) * 2005-10-17 2015-10-06 Memorial Sloan Kettering Cancer Center Wt1 hla class ii-binding peptides and compositions and methods comprising same
CN102250211A (zh) * 2006-02-22 2011-11-23 株式会社癌免疫研究所 Hla-a*3303限制性wt1肽和包含此肽的药物组合物
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
CN100460013C (zh) * 2006-09-05 2009-02-11 重庆康卫生物科技有限公司 口服重组幽门螺杆菌疫苗及其制备方法
CA2886621A1 (en) * 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
AU2012227350C1 (en) * 2006-12-28 2015-11-12 International Institute Of Cancer Immunology, Inc. HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same
PL2119778T3 (pl) * 2007-02-27 2016-04-29 Int Inst Cancer Immunology Inc Sposób aktywacji pomocniczej komórki T oraz kompozycja do zastosowania w tym sposobie
US10093977B2 (en) 2007-03-05 2018-10-09 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
KR101238795B1 (ko) * 2007-05-24 2013-03-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 동결건조 항원 조성물
MX2010002002A (es) * 2007-08-20 2010-03-11 Oncotherapy Science Inc Peptido foxm1 y agente medicinal que lo contiene.
WO2009066462A1 (ja) * 2007-11-20 2009-05-28 Nec Corporation 細胞傷害性ｔ細胞の誘導方法、細胞傷害性ｔ細胞の誘導剤、およびそれを用いた医薬組成物およびワクチン
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
AR076349A1 (es) * 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
EP2483417B1 (de) * 2009-09-29 2017-03-29 The Trustees Of The University Of Pennsylvania Verfahren zur diagnose und/oder behandlung von enzephalitis oder epilepsie
NZ609460A (en) 2010-10-05 2015-07-31 Otsuka Pharma Co Ltd Method for activating helper t cell
CN102161998B (zh) * 2011-01-14 2013-01-09 中国人民解放军军事医学科学院附属医院 基于b7-1-pe40kdel外毒素融合基因的dna疫苗及其用途
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
KR20140039318A (ko) 2011-06-28 2014-04-01 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 펩티드 암 항원 특이적 ｔ 세포의 리셉터 유전자
US9851356B2 (en) 2011-09-14 2017-12-26 International Institute Of Cancer Immunology, Inc. Method for measuring anti-WT1 antibody
CA2861206C (en) 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof
PL2931304T3 (pl) * 2012-12-13 2021-11-08 The Trustees Of The University Of Pennsylvania Szczepionka wt1
EA201591168A1 (ru) 2012-12-17 2016-05-31 Оцука Фармасьютикал Ко., Лтд. Способ активации хелперной t-клетки
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN110078813B (zh) * 2013-01-15 2023-03-28 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
KR102045029B1 (ko) * 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
WO2014144885A2 (en) * 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
CA2912514A1 (en) * 2013-05-13 2014-11-20 International Institute Of Cancer Immunology, Inc. Method for predicting clinical effect of immunotherapy
CN110511960B (zh) 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
US10253075B2 (en) 2014-02-26 2019-04-09 tella, Inc. WT1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
EP3137105A4 (de) 2014-04-30 2017-12-27 President and Fellows of Harvard College Kombinationsimpfstoffvorrichtungen und -verfahren zur abtötung von krebszellen
SMT202200370T1 (it) 2015-11-20 2022-11-18 Memorial Sloan Kettering Cancer Center Composizione per il trattamento del cancro
CN105254760B (zh) * 2015-11-21 2018-08-17 福州迈新生物技术开发有限公司 一株分泌抗wt1蛋白的单克隆抗体及其应用
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
EP3484448B1 (de) 2016-07-13 2025-04-09 President and Fellows of Harvard College Antigenpräsentierende zellmimetische gerüste und verfahren zur herstellung und verwendung davon
RU2770060C2 (ru) 2016-08-02 2022-04-14 Президент Энд Феллоуз Оф Гарвард Колледж Биологические материалы для модуляции иммунных ответов
MX2019003176A (es) * 2016-09-23 2019-07-04 Hutchinson Fred Cancer Res Receptores de linfocitos t (tcr) especificos del antigeno menor de histocompatibilidad (h) ah-1 y sus usos.
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
EP3604325A4 (de) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. Wt1-krebs-antigen-peptid und peptid-konjugat-körper damit
WO2018227205A1 (en) * 2017-06-09 2018-12-13 President And Fellows Of Harvard College Compositions for inducing an immune response
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
KR20210068060A (ko) 2018-09-28 2021-06-08 다이니뽄 스미토모 세이야쿠 가부시키가이샤 주사용 조성물
EP4034148A4 (de) 2019-09-23 2025-09-10 Harvard College Biomaterialbasierter antigenfreier impfstoff und verwendung davon
MX2022014249A (es) 2020-05-12 2023-02-22 Sumitomo Pharma Co Ltd Composición farmacéutica para tratar el cáncer.
CN118076382A (zh) * 2021-08-12 2024-05-24 株式会社癌免疫研究所 用于治疗或预防癌症的药用组合物和方法
CN113730562B (zh) * 2021-09-10 2024-06-04 中国人民解放军陆军军医大学 以壳聚糖修饰plga的wt1多肽纳米粒疫苗及其制备方法和应用

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US18795A (en) * 1857-12-01 James s
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4673562A (en) 1983-08-19 1987-06-16 The Children's Medical Center Corporation Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4708930A (en) 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4735792A (en) 1987-04-28 1988-04-05 The United States Of America As Represented By The United States Department Of Energy Radioiodinated maleimides and use as agents for radiolabeling antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE10399031I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AU2613988A (en) 1988-01-04 1989-08-01 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5631154A (en) 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
ES2084698T5 (es) 1989-05-04 2005-03-01 Southern Research Institute Procedimiento de encapsulacion.
EP0487587A1 (de) 1989-08-18 1992-06-03 Chiron Corporation Rekombinante retroviren um vektorkonstruktionen an zielzellen zu liefern
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5726288A (en) * 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
WO1991007509A1 (en) * 1989-11-13 1991-05-30 Massachusetts Institute Of Technology Localization and characterization of the wilms's tumor gene
ATE162219T1 (de) 1989-11-16 1998-01-15 Univ Duke Transformation von tierischen hautzellen mit hilfe von partikeln
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
WO1991016116A1 (en) 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
DE69128898T2 (de) 1990-08-15 1998-05-28 Therion Biolog Corp Selbstständig zusammenfügende replikationsdefekte hybride viruspartikel
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
EP0553288B1 (de) 1990-10-18 1997-06-18 Cellpro Incorporated Vorrichtung und verfahren zur trennung von partikeln mittels eines biegsamen gefässes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
AU671971B2 (en) * 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JPH08505625A (ja) 1993-01-11 1996-06-18 ダナ−ファーバー キャンサー インスティチュート 細胞毒性ｔリンパ球応答の誘導
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
CA2147991A1 (en) 1993-09-01 1995-03-09 Richard A. Glennon Tryptamine analogs with 5-ht1d selectivity
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1293559B1 (de) 1994-01-21 2005-07-27 Powderject Vaccines, Inc. Gasbetätigtes Element zum Austragen von Genmaterial
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5670317A (en) * 1995-05-08 1997-09-23 Sloan-Kettering Institute For Cancer Research Diagnostic test for the desmoplastic small round cell tumor
ES2268705T3 (es) * 1995-06-01 2007-03-16 Kishimoto, Tadamitsu Inhibidor del crecimiento de celulas leucemicas que contienen un derivado oligonucleotidico antisentido frente al gen del tumor de wiloms (wt1).
US6165460A (en) 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
EP0871747A1 (de) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunstimulierung vermittelt durch genmodifizierte dendritische zellen
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
ATE249240T1 (de) 1998-02-12 2003-09-15 Immune Complex Corp Strategisch modifizierte hepatitis b kernproteine und ihre derivate
EP1068339B1 (de) * 1998-04-01 2008-07-23 The Governors of the University of Alberta Zusammensetzungen und verfahren zur protein-sekretion
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
EP1104306B1 (de) 1998-08-10 2006-01-11 Antigenics Inc. Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
PL201881B1 (pl) * 1998-09-30 2009-05-29 Corixa Corp Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma

Also Published As

Publication number Publication date
DE60232102D1 (de) 2009-06-04
WO2003037060A3 (en) 2004-08-12
AU2002361584B2 (en) 2009-07-23
NZ533220A (en) 2008-04-30
US20030235557A1 (en) 2003-12-25
KR20050042226A (ko) 2005-05-06
DK1468014T3 (da) 2009-08-10
CN1671733A (zh) 2005-09-21
EP2172476A3 (de) 2010-06-23
CN100471868C (zh) 2009-03-25
EP1468014A4 (de) 2006-05-17
EP1468014B1 (de) 2009-04-22
WO2003037060A2 (en) 2003-05-08
CA2465303A1 (en) 2003-05-08
JP2005518192A (ja) 2005-06-23
ES2326311T3 (es) 2009-10-07
NZ560858A (en) 2009-06-26
KR100970854B1 (ko) 2010-07-20
CY1111002T1 (el) 2015-06-11
JP4391232B2 (ja) 2009-12-24
EP1468014A2 (de) 2004-10-20
EP2172476A2 (de) 2010-04-07
CA2465303C (en) 2011-09-13

Similar Documents

Publication Publication Date Title
DE60232102D1 (de) Zusammensetzungen und Verfahren zur WT1-spezifischen Immuntherapie
ATE402189T1 (de) Verbindungen und methoden zur wt1-spezifischen immuntherapie
TW200509967A (en) Compositions and methods for WT1 specific immunotherapy
TW200606176A (en) Compositions and methods for wt1 specific immunotherapy
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
PL366575A1 (pl) Kompozycje oraz sposoby leczenia i diagnozowania raka jajnika
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
DE69942827D1 (de) Verwendung der epothilons zur behandlung der krebs
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
WO2003057146A3 (en) Novel compositions and methods for cancer
DE602004030541D1 (de) Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
DE69942637D1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
ATE330626T1 (de) Arzneimittel zur immuntherapie maligner tumoren
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
WO2003071933A3 (en) Novel compositions and methods for cancer
AU2003261102A1 (en) Novel polynucleotide and polypeptide sequences and uses thereof
WO2003081250A8 (en) Novel compositions and methods in cancer associated with altered expression of prlr
DK1708693T3 (da) Farmaceutiske sammensætninger indeholdende platinkomplekser med sekundære xanthater og terapeutiske anvendelser deraf
WO2003079977A3 (en) Novel compositions and methods in cancer associated with altered expression of mcm3ap
ATE327240T1 (de) 2ß OXO-VORUSCHARIN UND DERIVATEN

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1468014

Country of ref document: EP